References
1. Ball RJ, Avenell A, Aucott L, Hanlon P and Vickers MA (2015) Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis.Arthritis Res Therap 17: 274
2. Hislop AD, Taylor GS, Suace D, Rickinson AB. (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.Ann Rev Immunol 25: 587-617.
3. Crombie JL, LaCasce AS. (2019) Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol . 9:109.
4. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol . 32:798-808. doi: 10.1200/JCO.2013.51.5304
5. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttranplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131
6. Kazi S, Mathur A, Wilkie GM, Cheal K, Battle R, McGowan N, Fraser N, Hargreaves E,, et al (2019) Long-term follow up after third party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.Haematologica 104:e356-e359. doi: 10.3324
7. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, et al (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy proven EBV+ lymphoma after allogeneic hematopoietic cell transplantation.Blood 119: 2644-55.
8. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, et al (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121:5113–5123
9. Prockop SE, Doubrovina E, Feng A, Koehne G, Dahi P, et al (2018) Long-term outcome of Tabelecleucel (Third-party allogeneic EBV-targeted cytotoxic T-lymphocytes) for Rituximab-refractory post-transplant EBV + lymphomas: a single centre experience. Poster PF401. Presented on June 15, 2018 at 23rd Congress of the European Hematology Association (EHA)
10. Pallesen G, Hamilton-Dutoit SJ, & Zhou X (1993) The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin’s disease: two new developments in the EBV field. Advances Cancer Res 62, 179-239
11. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Roussea A, Sixbey J, Gresik MV, et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200: 1623-1633
12. Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Almot PL, Crawford DH, et al (2004) Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother 27:309-16.
13. Hao QF, Yang YX, Wang Y, Chen LM, Sheng GY & Luan Z (2014) Rapid generation of Epstein-Barr virus-specific T cells for cellular therapy.Transplant Proc 46:21-5
14. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, et al (2010) Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunotherapy 33 (3), 305-315
15. Bollard CM, Gottschalk S, Huls H, Leen AM, Gee AP & Rooney CM (2011) Manufacture of GMP-grade cytotoxic T lymphocytes specific for LMP1 and LMP2 for patients with EBV-associated lymphoma.Cytotherapy 13: 518-522
16. Lapteva N & Vera JF (2011) Optimization manufacture of virus- and tumor-specific T cells. Stem Cells International 434392. doi: 10.4061/2011/434392434392
17. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM & Rooney CM (2012) Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy 14: 7-11
18. McLaughlin LP, Gottschalk S, Rooney CM & Bollard CM (2017) EBV-directed T cell Therapeutics for EBV-associated lymphomas.Methods Mol Biol 1532: 255-265
19. Cox MA, Kahan SM & Zajac AJ (2013) Anti-viral CD8 T cells and the cytokines that they love. Virology 435, 157-169
20. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, Barry J, Fraser N, et al (2014) Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 167, 402–410
21. Campbell JDM & Fraser AR (2018) Flow Cytometric Assays for Identity, Safety and Potency of Cellular Therapies. Cytometry Part B (Clin Cytom) 94B:569–579
22. Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA & Kedl RM (2013) T cell responses: naive to memory and everything in between. Adv Physiol Education 37 (4), 273-283
23. Kared H, Martelli S, Ng TP, Pender SL & Larbi A (2016) CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 65:441-52
24. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, et al (2014) Optimizing the production of suspension cells using the G-Rex “M” series. Molecular Therapy – Methods & Clinical Development 1, 14015
25. Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR & Riddell SR (2016) Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol 28:28-34.
26. Klebanoff CA, Gattinoni L & Restifo NP (2012) Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother 35:651-60.
27. Shourian M, Beltra JC, Bourdin B & Decaluwe H (2019) Common gamma chain cytokines and CD8 T cells in cancer. Semin Immunol . 42:101307.
28. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, et al (2019) Defining ’T cell exhaustion’. Nat Rev Immunol . 2019 Sep 30. doi: 10.1038/s41577-019-0221-9. [Epub ahead of print]
29. Merlo A, Turrini R, Trento C, Zanovello P, Dolcetti R & Rosato A (2010) Impact of γ-chain cytokines on EBV-specific T cell culturesJ Transl Med 8: 121 doi: 10.1186/1479-5876-8-121
30. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, et al. (2013) Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31:39-48.
31. Horlock C, Skulte A, Mitra A, Stansfield A, Bhandari S, Ip W, Qasim W, Lowdell MW, et al (2016) Manufacture of GMP-compliant functional adenovirus specific T-cell therapy for treatment of post-transplant infectious complications. Cytotherapy 18: 1209-1218
32. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, et al (2013) Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Therapy 21: 2113-2121
33. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, et al (2017) Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 35:3547-3557.
34. Khalaf WS, Garg M, Mohamed YS, Stover CM, Browning MJ. (2019) In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma. Front Immunol. 10:1792. doi: 10.3389/fimmu.2019.01792.
35. Chicaybam L, Abdo L, Carneiro M, Peixoto B, Viegas M, de Sousa P, Fornazin MC, Spago MC et al. (2019) CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo. Hum Gene Ther. 30:511-522. doi: 10.1089/hum.2018.218.
36. Sánchez-Martínez D, Azaceta G, Muntasell A, Aguiló N, Núñez D, Gálvez EM, Naval J, Anel A, et al (201 Human NK cells activated by EBV(+) lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.Oncoimmunology .4:e991613. doi: 10.4161/2162402X.2014.991613.
37. Cooper RS, Fraser AR, Smith L, Burgoyne P, Imlach SN, Jarvis LM, Zahra S, Turner ML, Campbell JDM (2020) Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19. BioRxiv. doi: https://doi.org/10.1101/2020.08.05.23786.